Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term

Stock Information for Nymox Pharmaceutical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nymox Pharmaceutical Corporation

Nymox Delisting from NASDAQ
Nymox Provides Current Update
Nymox Provides Corporate Update
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
Nymox Officially Granted Extension to Regain Listing Requirements
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
NYMOX Appeals Deficiency Letter
NYMOX Announces New Marketing Submission for NYMOZARFEX(TM) for BPH

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.